07/01/2026
ONS Advocacy News: New ASCO findings on GLP‑1s suggest they may reduce metastatic progression in certain cancers — a development with big clinical and policy implications. While safety signals are limited, cost and access could widen disparities. Read the latest from ASCO and ONS steps to support patients and workplaces. Read more: https://wix.to/js4E6Ne
In the most recent ONS Advocacy email, information from a study presented ASCO detailed unexpected effects of GLP-1s on reducing metastatic progression of certain cancers has created quite a stir. There are many things to be considered, while the study notes no significant safety concerns, expense a...